Hims & Hers adds compounded semaglutide pills starting at $49 monthly
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Hims & Hers adds compounded semaglutide pills starting at $49 monthly
February 6, 2026 6:04 AM EST
TD Cowen analyst Jonna Kim reiterated a Hold rating and $30.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "We are hosting a Pharmacy Law Expert Call: An Update On Oral And Injectable GLP-1 Compounding today (2/6) at 12:30pm ET - please contact your sales representative if you are interested.
HIMS announced that the launch of compounded semaglutide pills starting at $49 the first month with a 5 month-plan (remaining months at $99 per month). Our take is that without this announcement, compounded GLP-1 revenue would... More
February 5, 2026 10:25 AM EST
Leerink Partners analyst Michael Cherny reiterated a Market Perform rating and $41.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bottom Line: The compounded oral semaglutide launch announcement today is another clear example of HIMS' strategy to leverage customization and the... More
